The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...

Wall Street chugged mostly higher in premarket trading as Chinese and U.S. officials begin a second day of trade talks.

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Novo Nordisk A/S lowered its financial forecast in a surprise update that cited lagging sales of its weight-loss drug Wegovy, as the company fights to regain its leading position in the obesity market ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and opera ...

Novo Nordisk has revised its 2025 sales and profit expectations downward for the second time, facing tough competition from ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...